WALTHAM, Mass. — January 5, 2026 — Leads & Copy — ElevateBio has appointed Christopher Murphy as its new Chief Executive Officer (CEO) and a member of its Board of Directors.
Murphy succeeds Ger Brophy, Ph.D., who served as interim CEO since May 2025. Brophy will remain with ElevateBio as a strategic and technology advisor.
Murphy brings over 35 years of leadership and operational experience in the biopharmaceutical and manufacturing sectors. His background includes expertise in advanced therapeutic development, manufacturing, commercial operations, and management, which he will use to accelerate revenue growth and build scalable businesses. ElevateBio believes his experience will guide the company’s growth, focusing on scaling the business through partnerships.
According to David Hallal, Executive Chairman of ElevateBio, Murphy’s experience in development and large-scale manufacturing is essential as more partners entrust ElevateBio with their programs as they mature and require product for commercialization. Hallal also thanked Brophy for his leadership as interim CEO.
Before joining ElevateBio, Murphy was CEO of Akron Bio, where he led a transformation of the organization. He previously served as Chief Operating Officer of Brammer Bio, overseeing viral vector development and manufacturing across four sites. Following Thermo Fisher Scientific’s acquisition of Brammer Bio in 2019, Murphy served as Vice President and General Manager of Viral Vector Services at Thermo Fisher. He also held leadership positions at Sanofi Genzyme, managing the company’s manufacturing site for Cerezyme®.
Murphy holds an M.S. in Biochemistry from New York Medical College and a B.S. in Biological Sciences from Rutgers University.
Murphy said he is honored to join ElevateBio, a company that has established itself as a leader in advanced therapies. He added that ElevateBio is positioned to advance the cell and gene therapy field, and to take the next step, the company will grow and expand partnerships across its manufacturing services and gene editing platform, industrialize workflows and establish new standards for the industry to make a tangible impact on the lives of patients and their families.
ElevateBio is a technology-driven company focused on powering the creation of genetic medicines. It commercializes its technologies, manufacturing capabilities, and expertise through partnerships to accelerate development across therapeutic approaches and modalities. The ElevateBio ecosystem combines Life Edit®, its gene editing technologies and R&D business, with BaseCamp®, its end-to-end genetic medicine process development and cGMP manufacturing business, to accelerate the discovery and development of advanced therapeutics.
ElevateBio aims to use human cells and genes to alter disease.
Contact:
Catherine Hu
chu@elevate.bio
Source: ElevateBio
